Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-24-016984.pdf
0001415889-24-016984.rtf
0001415889-24-016984.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-24-016986.pdf
0001415889-24-016986.rtf
0001415889-24-016986.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-24-016983.pdf
0001415889-24-016983.rtf
0001415889-24-016983.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-24-016985.pdf
0001415889-24-016985.rtf
0001415889-24-016985.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-24-016987.pdf
0001415889-24-016987.rtf
0001415889-24-016987.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-24-015943.pdf
0001415889-24-015943.rtf
0001415889-24-015943.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-24-015734.pdf
0001415889-24-015734.rtf
0001415889-24-015734.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-24-015540.pdf
0001415889-24-015540.rtf
0001415889-24-015540.xls
144

Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing

 View HTML
0001972362-24-000845.pdf
0001972362-24-000845.rtf
0001972362-24-000845.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-24-015315.pdf
0001415889-24-015315.rtf
0001415889-24-015315.xls